A new survey by
Strategy&, PwC’s strategy consulting business, has found that pharmaceutical
executives generally aren’t inclined to spend more to fight fakes, despite
their awareness that current measures don’t go far enough. Not only do these
executives misjudge their own vulnerability, but they also overlook the
opportunities awaiting those that capitalize on rapidly evolving
anti-counterfeiting technologies that do more than improve on existing supply
chain safeguards. Companies that adopt these technologies will reap a range of
new benefits, and gain an edge over rivals relying on yesterday’s solutions.
With this in mind, we decided to take a look at the top three reasons to
capitalize on new anti-counterfeiting and brand protection technologies this
year.
Please note: That all fields marked with an asterisk (*) are required.